{"disease":{"id":"advanced-clear-cell-renal-cell-carcinoma-or-other-advanced-solid-tumors","name":"advanced clear cell renal cell carcinoma or other advanced solid tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06191796","title":"Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"Exelixis","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}